UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech, previously ...
UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed ...
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY ...
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $10.00. The company’s shares opened ...
"Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to ...
Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Unity Biotechnology in a research ...
Chardan Capital restated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX – Free Report) in a report issued on Wednesday,Benzinga reports. The brokerage currently has a $4.00 target price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback